Release date: 2014-08-05
The investment focus of the US mobile medical industry is quietly changing. From the past to the wearable devices and health tracking products, it has gradually shifted to products for medical service organizations. The investment hotspots include: medical data applications and doctor-patient interaction.
Of the seven start-up projects selected by the New York Digital Health Accelerator announced in July 2014, only one is for consumer products (Noom free weight loss coach), and the remaining six are professional. Very strong, for the organization's products.
These products can be roughly divided into two categories. One is data analysis and application classes, such as Allazo Health, which predicts patient medication habits through patient drug analysis; Clinigence, which analyzes clinical data to help doctors improve service efficiency; and integrates and analyzes electronic medical records, drug management, etc. iQuartic for doctors to make the best treatment; there is another Covertix that protects privacy and confidential data.
The second category is tools that help health care providers interact with patients, such as Quality Reviews, through RateMyHospital.com, which provides hospitals and private doctors with a service-based questionnaire that provides timely feedback from patients; and helps doctors and medical institutions Sense Health, a tool for patient tracking and service management.
Different from the past investment direction, the project is more targeted and has smaller entry points for the first type of data application products. The concept of medical data, which has been very hot in investment, especially for big data applications, has proved that many projects are too cumbersome to operate, and the operational methods and clinical applications are not efficient.
The current investment trend is biased towards the activation of medical data that is not currently active. For example, the EHR electronic medical record is a good entry point. Hospitals and private clinics have a large amount of EHR data that is more direct, accurate, and effective than data collected from consumer and wearable devices. However, in the past, these data have been in a state of sleep. The hospital has no technical means and talents to apply the data, and the meaning behind these data may be very large, such as predicting a patient's medication habits and their health effects, from electronic medical records. It can be seen that the effectiveness of the diagnosis, the patient's wastage rate, can help improve the quality of service and retain the patient.
The entry point is smaller but more accurate, and investors are optimistic about the impact of these data applications on clinical decision-making. Moreover, this round of investment has begun to transform to serve institutions rather than individuals. The core of the project is to help medical services save costs and energy and improve services.
The second category of products is to help institutions and patients communicate and interact. Projects invested in the past, such as hospital reviews and doctor-patient interaction projects, are mostly patient-centered, but it is difficult to charge patients from a profit perspective. The current investment trend is to provide services to institutions.
For example, Quality Reviews mentioned above provides a platform for the hospital to design questionnaires and a platform for patients to respond directly through RateMyHospital.com to help hospitals evaluate their services and get patient feedback in a timely manner. The core of such products has been to attract patients from the past to serve the institutions. In the past, similar patient review services can gather a large number of patient feedback, but the data is very scattered, meaning little to the hospital. The current investment focus is to provide a platform for hospitals and patients to communicate, to help the hospital collect feedback data. These questionnaires are effective, the hospital is willing to pay, and the past projects from the patient side can not be charged from the patient.
The quiet shift of this investment hot spot shows that the US market's perception of mobile medical products is beginning to change. In the past, the investment ideas of relying on hype products and attracting people's attention have finally proved that many projects cannot survive alone and have to rely on selling or burning money to expand. scale. The investment shift will be more focused on clinical applications, focusing on products that can truly serve healthcare organizations, with the primary goal of improving service efficiency, helping doctors' clinical judgment, and providing a platform for direct patient feedback. These projects have a higher probability of survival because they effectively address the needs of medical institutions and medical institutions are willing to pay for services. However, the startup team is also required to have a relatively strong medical institution resources, which will be extremely important when promoting.
Source: Bio Valley
Carnitine, or trans. carnitine, is an amino acid, a quaternary ammonium cationic complex, which can be biosynthesized from both lysine and methionine and is involved in the metabolism of fat into energy in the body. Carnitine has two stereoisomerism: L-Carnitine, which is biologically active, and D-carnitine, which is non-biologically active. L-carnitine (L-carnitine) is an amino acid widely distributed in the liver, especially in myocardium and skeletal muscle. Most of the carnitine required by the body comes from meat and dairy products in the diet. [1]
Carnitine is an amino acid widely distributed in the liver, especially in cardiac muscle and skeletal muscle. Most of the carnitine components required by the body come from meat and dairy products in the diet. In addition, the body itself can synthesize part of methionine as raw material, and the body needs vitamin C, iron, B6 and niacin as auxiliary factors of various enzymes in the reaction when biosynthesizing carnitine. L-carnitine is widely present in the body, especially in mitochondria. The concentration of L-carnitine was highest in the adrenal gland, followed by the heart, bone, muscle, adipose tissue and liver. Free L-carnitine is excreted in the urine. Plant-based foods contain less l-carnitine (in some cases none), as well as less lysine and methionine, the two essential amino acids that make carnitine. The l-carnitine content in animal food is high, especially in liver. Foods rich in L-carnitine include yeast, milk, liver, meat and other animal foods. Humans and most animals can also meet their physiological needs through synthesis within their bodies. L-carnitine is not deficient under normal conditions.
Gw-501516 Sarm Cardarine,Sarm Cardarine Gw 501516,Endurobol Gw501516 Powder
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropic.com